Pipeline

Our diabetes lead candidate NDC-0009 has shown efficacy as a disease modifying treatment in several animal and human models of both Type 1 and Type 2 Diabetes. In addition to regulating glucose and improving insulin secretion and response, this molecule also protects pancreatic beta cells in human tissues. We have initiated required IND-enabling studies with plans to submit the application to the FDA within the next 8-12 months.

Neurodon’s Alzheimer’s program is currently in late lead optimization status with several potential development candidates identified. In collaboration with the National Institute on Aging of the NIH, we are currently performing several pivotal efficacy and safety studies to prioritize our lead candidates.

We have identified several orally-available molecules that show compelling efficacy in animal models of Parkinson’s disease. These candidates are currently undergoing lead optimization with the goal of selecting development candidates later this year.

In collaboration with our academic colleagues, we have identified molecules that show efficacy in diverse rare diseases such as Huntington’s disease, muscular dystrophy, and other indications. These molecules are in various stages of development with the potential for rapid acceleration to clinical status due to their orphan status.